Sanaria, malaria program to begin human trials of novel vaccine

04/23/2009 | American City Business Journals

Biotech firm Sanaria and the Path Malaria Vaccine Initiative are preparing to launch the first human trials of a vaccine that contains a weakened version of an entire malaria parasite found in radiation-zapped mosquitoes. The groups plan to enroll 104 healthy volunteers and expect to treat the first patient in mid-May.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care